Minireviews
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 21, 2018; 24(35): 4021-4027
Published online Sep 21, 2018. doi: 10.3748/wjg.v24.i35.4021
Biosimilars in paediatric inflammatory bowel disease
Joanna Sieczkowska-Golub, Dorota Jarzebicka, Grzegorz Oracz, Jaroslaw Kierkus
Joanna Sieczkowska-Golub, Dorota Jarzebicka, Grzegorz Oracz, Jaroslaw Kierkus, The Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, The Children’s Memorial Health Institute, Warsaw 04-730, Poland
Author contributions: All authors contributed equally to this paper including concept and design, literature review and analysis, preparation of the draft manuscript, critical revision and editing, and approval of the final version.
Conflict-of-interest statement: Kierkus J has received speaker fees from Egis and AbbVie.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jaroslaw Kierkus, MD, PhD, Full Professor, The Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, The Children’s Memorial Health Institute, Aleja Dzieci Polskich 20, Warsaw 04-730, Poland. j.kierkus@med-net.pl
Telephone: +48-22-8157392 Fax: +48-22-8157382
Received: June 7, 2018
Peer-review started: June 7, 2018
First decision: July 12, 2018
Revised: August 14, 2018
Accepted: August 24, 2018
Article in press: August 24, 2018
Published online: September 21, 2018
Processing time: 106 Days and 5.4 Hours
Core Tip

Core tip: Data on the use of biosimilars among paediatric patients are limited. Nevertheless, several original papers support adult findings that biosimilars are as effective and safe as the reference infliximab in this population.